Recombinant multi-species SUMF2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SUMF2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The catalytic sites of sulfatases are only active if they contain a unique amino acid, C-alpha-formylglycine (FGly). The FGly residue is posttranslationally generated from a cysteine by enzymes with FGly-generating activity. The gene described in this record is a member of the sulfatase-modifying factor family and encodes a protein with a DUF323 domain that localizes to the lumen of the endoplasmic reticulum. This protein has low levels of FGly-generating activity but can heterodimerize with another family member - a protein with high levels of FGly-generating activity. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
The Alternative Names of target: SUMF2,Inactive C-alpha-formylglycine-generating enzyme 2,Paralog of formylglycine-generating enzyme (pFGE), Sulfatase-modifying factor 2,pFGE

Target products collectionGo to SUMF2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0608-Ab-1/ GM-Tg-hg-SE0608-Ab-2 Human SUMF2 protein Human
GM-Tg-rg-SE0608-Ab-1/ GM-Tg-rg-SE0608-Ab-2 Rat SUMF2 protein Rat
GM-Tg-mg-SE0608-Ab-1/ GM-Tg-mg-SE0608-Ab-2 Mouse SUMF2 protein Mouse
GM-Tg-cynog-SE0608-Ab-1/ GM-Tg-cynog-SE0608-Ab-2 Cynomolgus/Rhesus macaque SUMF2 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0608-Ab-1/ GM-Tg-felg-SE0608-Ab-2 Feline SUMF2 protein Feline
GM-Tg-cang-SE0608-Ab-1/ GM-Tg-cang-SE0608-Ab-2 Canine SUMF2 protein Canine
GM-Tg-bovg-SE0608-Ab-1/ GM-Tg-bovg-SE0608-Ab-2 Bovine SUMF2 protein Bovine
GM-Tg-equg-SE0608-Ab-1/ GM-Tg-equg-SE0608-Ab-2 Equine SUMF2 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0608-Ab-1/ GM-Tg-hg-SE0608-Ab-2; GM-Tg-rg-SE0608-Ab-1/ GM-Tg-rg-SE0608-Ab-2;
GM-Tg-mg-SE0608-Ab-1/ GM-Tg-mg-SE0608-Ab-2; GM-Tg-cynog-SE0608-Ab-1/ GM-Tg-cynog-SE0608-Ab-2;
GM-Tg-felg-SE0608-Ab-1/ GM-Tg-felg-SE0608-Ab-2; GM-Tg-cang-SE0608-Ab-1/ GM-Tg-cang-SE0608-Ab-2;
GM-Tg-bovg-SE0608-Ab-1/ GM-Tg-bovg-SE0608-Ab-2; GM-Tg-equg-SE0608-Ab-1/ GM-Tg-equg-SE0608-Ab-2
Products Name SUMF2 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name SUMF2
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SUMF2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.